Eligibility for icosapent ethyl in a French population of coronary outpatients with type 2 diabetes.

Authors:
Sabouret PF; Dib JC; Ecarnot F; Banach M; Lellouche N.

Journal:
Arch Med Sci

Publication Year: 2023

DOI:
10.5114/aoms/173511

PMCID:
PMC10696963

PMID:
38058709

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Arch Med Sci

Abbreviation: Arch Med Sci

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Medicine, General & Internal

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Atypical presentation of Lyme disease.
Jarosińska A; Pilśniak A; Cieśla-Fuławka A and 3 more (2024) - Transparency Score: 2/6
Cuproptosis-related genes are involved in immunodeficiency following ischemic stroke.
Jinshi L; Cong Y; Liang S and 2 more (2024) - Transparency Score: 3/6
Efficacy of ornidazole for pericoronitis: a meta-analysis and systematic review.
Du R; Ba K; Yang Y and 2 more (2024) - Transparency Score: 2/6
Interleukins: pathophysiological role in acute pancreatitis.
Rafaqat S; Patoulias D; Behnoush AH and 2 more (2024) - Transparency Score: 3/6
Level of basic hope and symptoms of anxiety and depression in women after miscarriage.
Białek K; Sadowski M; Adamczyk-Gruszka O and 2 more (2024) - Transparency Score: 2/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of interest P.S. declares that he has received speaker fees from Astra Zeneca, Axis TV, BMS, Les laboratoires Servier, Novartis, Novonordisk, Sanofi, and Vifor, outside the present work. F.E. declares speaker fees from Sanofi and consultant fees from GlaxoSmithKline, outside of the present work. M.B. declares: speakers bureau: Amgen, KRKA, Polpharma, Novartis, Sanofi-Aventis, Teva, Zentiva; consultant to Amgen, Daichii Sankyo, Esperion, Novartis, Sanofi-Aventis; grants from Amgen, Sanofi and Valeant. N.L. declares consultant fees from BMS, Bayer outside the present work. JCD has no conflict of interest to declare."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025